We have read the paper “Compromised adult height in females with non-classical congenital adrenal hyperplasia diagnosed in childhood” by R. Bello, L. Lazar, M. Phillip, and L. de Vries [1] with great interest. Although reduced final height is a common consequence in adults with classic congenital adrenal hyperplasia (CAH), final height data in untreated non-classic CAH (NCCAH) are scarce, and the effect of glucocorticoid treatment to improve final height is still under debate [2]. Therefore, studies evaluating the natural course of height in patients with NCCAH can add important knowledge.In this article, the authors present data on a large group of females with NCCAH who reached their final height. They showed that the final height was significantly below the target height in this group. Based on their findings, the authors suggest that the androgen excess in these patients, rather than the glucocorticoid treatment, is the main cause of the compromised adult height. We question whether the methodology of this study is sufficient to draw this conclusion as confounding bias could have interfered with the study results, and therefore we would like to make some contributions.In this study, the diagnosis was not genetically confirmed in 27% of the patients. Therefore, inclusion of more severe forms of CAH, such as simple virilizing CAH, cannot be ruled out, especially in those patients with strongly elevated 17OHP levels. A more severe genotype can also be considered in those patients who developed symptoms at a very young age. The high prevalence of central precocious puberty (CPP) and early puberty (EP) also suggests the possible inclusion of patients with a more severe genotype. Moreover, the presence of CPP or EP in these patients might contribute to a decreased adult height [3], irrespective of the NCCAH itself. A statistical approach to correct for the disease severity or presence of CPP/EP could help draw more robust conclusions.Furthermore, the authors included patients from 1986 to 2017. During this period, treatment recommendations changed significantly, resulting in heterogeneity of the treatment. In addition, no results are presented on follow-up and treatment compliance. Interestingly, 17 patients were never treated with glucocorticoids. In these patients, the final height would be of special interest. It could be valuable to describe them separately to gain knowledge about the natural course of NCCAH.Further studies, including prospective controlled studies, are necessary to study the effects of glucocorticoids on final height in NCCAH in more detail. As these studies are hard to perform, retrospective studies can be done, but it is important to homogenize the group as much as possible or to correct for bias in the statistical approach.The authors have no conflicts of interest to declare.The authors declare that no financial support was received.All authors contributed substantially to the work, critically reviewed the content, gave final approval for publication, and are accountable for all aspects of the work.